<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143803</url>
  </required_header>
  <id_info>
    <org_study_id>OI-005-2017</org_study_id>
    <nct_id>NCT03143803</nct_id>
  </id_info>
  <brief_title>Control of Blood Glucose Fluctuation With Usage of Polyherbal</brief_title>
  <official_title>Control of Glycemic Variability Using a Polyherbal: A Randomized Placebo Controlled Study of Whole Herb Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Composite Interceptive Med Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Composite Interceptive Med Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to get insight into control of glycemic variability with Sugar&#xD;
      Balance capsules which is the leaves of three herbs: ivy ground (Coccinia indica)-200mg,&#xD;
      bougainvillia (Bougainvillea spectabilis)-30mg, Madagascar periwinkle (Catharanthus&#xD;
      rosea)-20mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The glycemic variability would be obtained at 14 days with the usage of Flash glucose&#xD;
      monitoring system manufactured by Abbott and outcomes would be compared at the end of&#xD;
      ambulatory glucose profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Actual">August 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean amplitude glycemic excursion</measure>
    <time_frame>14 days</time_frame>
    <description>To demonstrate that the difference in mean amplitude glycemic excursions among patients receiving polyherbal medication will be less than 1mmol/dL or 18mg/dL for a sampling frequency: 1 every 15 minutes over 14 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean estimated glycated hemoglobin</measure>
    <time_frame>14 days</time_frame>
    <description>Mean estimated glycated hemoglobin difference between test and placebo control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemia episodes</measure>
    <time_frame>14 days</time_frame>
    <description>Number of hypoglycemia episodes and duration of hypoglycemia in treatment group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Polyherbal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will contain an inert substance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyherbal capsule coccinia, bougainvillea, catharanthus</intervention_name>
    <description>A unique combination of 3 herbs that lower blood sugars</description>
    <arm_group_label>Polyherbal</arm_group_label>
    <other_name>Sugar Balance (SB)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar looking inactive powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult males and non-pregnant females aged ≥18 years having a diagnosis of pre-diabetes&#xD;
        (impaired fasting glucose or impaired glucose tolerance) or diabetes and meeting one of the&#xD;
        following criteria&#xD;
&#xD;
          1. Fasting Plasma Glucose ≥100 mg/dL, fasting defined as no caloric intake for at least 8&#xD;
             hours, AND&#xD;
&#xD;
          2. Glycosylated haemoglobin (A1C) ≥ 6 %. The test should be performed in a laboratory&#xD;
             using a method that is National Accreditation Board for Testing and Calibration&#xD;
             Laboratories certified and standardized within last 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any one of the following&#xD;
&#xD;
          1. Patients on Insulin therapy.&#xD;
&#xD;
          2. Any history suggestive of micro vascular or macro vascular disease - coronary artery&#xD;
             disease, stroke, peripheral artery disease or diabetes related retinal changes.&#xD;
&#xD;
          3. Women in child bearing age unable to practice any form of contraception&#xD;
&#xD;
          4. Patients with diagnosis of Anemia (Hb&lt;11 g/dl in Female and &lt;13 g/dl in Male)&#xD;
&#xD;
          5. Impaired renal function; estimated estimated glomerular filtration rate&#xD;
             &lt;60mls/min/1.73m2.&#xD;
&#xD;
          6. Known history of any chronic illness taking regular pharmacological agents.&#xD;
&#xD;
          7. Blood pressure fluctuations exceeding 20 mm of Hg on 2 subsequent clinic visits or&#xD;
             known history of hypo tension or bradycardia in last 6 months or taking 3 or more&#xD;
             anti-hypertensive medications regularly in the last 6 weeks&#xD;
&#xD;
          8. Known history of autonomic dysfunction like diabetic autonomic neural imbalance or&#xD;
             neuropathy&#xD;
&#xD;
          9. Current or former employees of organic India or any potential conflict of interest in&#xD;
             participation&#xD;
&#xD;
         10. Participating in another clinical trial with an active intervention or drug or device&#xD;
             with last dose taken within 60 days.&#xD;
&#xD;
         11. Refusing consent or physician uncomfortable with patient compliance to treatments or&#xD;
             follow up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alben Sigamani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Narayana Hrudayalaya Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mazumdar Shaw Medical Centre</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

